In summary, this brief report describes two important findings, the first is that the manipulation of EGFR glycosylation in ways that reduce signaling and dampen endpoints related to cancer progression can now be done with pharmacologically-relevant small molecules rather than the genetic approaches previously reported. The gene discussed is EGFR; the disease is cancer.